Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,777 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
Interventions
JAB-3068
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Conditions
Esophagitis
Interventions
omalizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Gastric Cancer, Colon Cancer, Esophageal Cancer, Rectal Cancer, Pancreatic Cancer, Gastrointestinal Cancer
Interventions
Phase 2 Intervention - Geriatric Co-Management
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Results available

HALO Patient Registry: Ablation of Barrett's Esophagus

NCT00848237
Conditions
Barrett Esophagus
Interventions
Radiofrequency Ablation (HALO Ablation Systems)
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
Not listed
Enrollment
5,521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Knoxville and Other US Cities, California
Conditions
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Interventions
CTX131
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Barrett Esophagus
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Not yet recruiting Not applicable Interventional

Enhancing Screening Practices for BE

NCT07335445
Conditions
Barrett's Esophagus
Interventions
Screening Reminder
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Gastro Esophageal Reflux
Interventions
dexlansoprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions
LY4052031, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 15 more
Conditions
Achalasia
Interventions
Per oral endolumenal myotomy
Procedure
Lead sponsor
The Oregon Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Gastric Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Biliary Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gastroesophageal Reflux Disease, Non Erosive Reflux Disease, Dyspepsia
Interventions
Confocal endomicroscopy, Proton pump inhibitor, Sucralfate
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Kenner, Louisiana • Charleston, South Carolina • Richmond, Virginia
Terminated Not applicable Interventional Results available

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NCT00619242
Conditions
Esophageal Cancer
Interventions
sorafenib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
Pamiparib, Temozolomide
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Grand Rapids, Michigan • St Louis, Missouri • New York, New York + 4 more
Conditions
Food Hypersensitivity, Anaphylaxis, Eosinophilic Esophagitis, Food Sensitivity, Food Intolerance, Food Allergy in Infants
Interventions
Not listed
Lead sponsor
Food Allergy Research & Education
Other
Eligibility
Not listed
Enrollment
23,000 participants
Timeline
2017 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
capecitabine, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Sioux City, Iowa • Sioux Falls, South Dakota
Conditions
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
Interventions
Q702, Pembrolizumab
Drug · Biological
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Louisville, Kentucky
Conditions
Esophageal Cancer, Esophageal Neoplasms
Interventions
Prehabilitation Program
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
panitumumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Conditions
Esophagogastric Junction Outflow Obstruction
Interventions
POEM
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Deglutition Disorders
Interventions
Aspirometer, Videofluoroscopic X-ray
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Short Segment Barrett's Esophagus, Long Segment Barrett's Esophagus
Interventions
Omeprazole, Vitamin D3, upper endoscopy, Metformin
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Beachwood, Ohio • Cleveland, Ohio
Completed Not applicable Interventional Results available

Endoesophageal Brachytherapy for Patients With Esophageal Cancer

NCT03335813
Conditions
Esophageal Cancer
Interventions
Endoesophageal Brachytherapy
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Weston, Florida